ConductScience.org, home

Cell line · CVCL_2142

NK-92

Cancer cell line, Homo sapiens. Natural killer cell lymphoblastic leukemia/lymphoma. 60 papers.

4 sourcescell-lines-2026-11-14-0.1.0

Download JSON
Cite this record

ConductScience Library. NK-92. Cell lines, record CVCL_2142. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_2142

On this page

Cell line

As Cellosaurus gives it.

Name
NK-92
Accession
CVCL_2142
RRID
RRID:CVCL_2142
Synonyms
NK92, Natural Killer-92, NK-92.05, Neukoplast, aNK
Species
Homo sapiens (Human)
Sex
Male
Age at sampling
50Y
Category
Cancer cell line
Diseases
Natural killer cell lymphoblastic leukemia/lymphoma (NCIt C82217)
Derived from
Peripheral blood (in situ)
Cell type
Natural killer cell
Entry created
2012-04-04
Entry updated
2026-06-25

Source Cellosaurus

Problems1

ProblemCellosaurus's note
Caution
This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.

Papers60

PaperJournalYearHow we knowRetractedSource
Hypoxic Preconditioning Restores NK Cell Metabolic Fitness by Attenuating MAPK Signaling to Potentiate Antitumor Immunity in Lung CancerAdv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
A metabolic-oxidative axis contributes to NK cell cryo-vulnerability.iScience2026Its Methods give the RRID and name the linePubMed
Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling.iScience2026Its Methods give the RRID and name the linePubMed
Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer.J Transl Med2026Its Methods give the RRID and name the linePubMed
Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells.PLoS One2026Its Methods give the RRID and name the linePubMed
The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity.Cell Commun Signal2026Its Methods give the RRID and name the linePubMed
Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway.Mol Cancer2026Its Methods give the RRID and name the linePubMed
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.Cancer Res2026Its Methods give the RRID and name the linePubMed
Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed

1 to 10 of 60

See all 60 papers

Relatives19

RelationCell lineAccessionProblemSource
Derived from itGFP-CD16-F/F.NK-92CVCL_W733Cell lines
Derived from itGFP-CD16-V/V.NK-92CVCL_W734Cell lines
Derived from itHyCyte NK-92 KO-hADORA2ACVCL_F4ISCell lines
Derived from itHyCyte NK-92 KO-hHMGB2CVCL_F1SLCell lines
Derived from itHyCyte NK-92 KO-hZYXCVCL_F1SMCell lines
Derived from itHyCyte NK-92 stable cell line for hCD64 overexpressionCVCL_F4LACell lines
Derived from itNK-92 GFPCVCL_VN56Cell lines
Derived from itNK-92 clone 1CVCL_C7GQCell lines
Derived from itNK-92 clone 2CVCL_C7GRCell lines
Derived from itNK-92.26.5CVCL_VN57Cell lines

Cell banks6

Cell bankCatalog numberStatusSource
ATCCCRL-2407ATCC
AddexBioC0003026/NADiscontinuedCellosaurus
BCRC60414DiscontinuedCellosaurus
CCTCCGDC0052Cellosaurus
DSMZACC-488DSMZ
HysigenTCH-C292Hysigen

Data dates

The date of each source this release read.

Cellosaurus
2026-10-22
Cellosaurus
PubMed Central's articles
2026-11-12
PubMed Central's articles
Our copy of PubMed
2026-11-06
Our copy of PubMed

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this cell line from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_2142

GET https://conductscience.org/api/cell-lines/v1/CVCL_2142/papers?page=2